VBI Vaccines Inc VBIV

Healthcare Biotechnology

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

NDAQ:VBIV - Post by User

VBI Vaccines Inc

Bullboard Posts

Post by BerkshireCapGrpon Jun 17, 2019 4:35pm

102 Views

Post# 29833173

VBIV .63~NASDAQ FROM $2.30 PREMARKET HOD! SUPER STEAL PRICES

VBIV We are buyers down here on the over reaction panic by traders. VBIV has $5 price target by CANACCORD lowered from $10 price target. This is a super bargain steal down here!

BIGGEST gains potential short term on our BOUNCE ALERT!

Bullboard Posts

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle